Tozadenant (CAS 870064-32-7) is a potent and selective adenosine A2A receptor antagonist. It is primarily investigated for its potential therapeutic applications in the treatment of Parkinson's disease. It functions by modulating the neurotransmitter systems involved in motor control. By blocking these receptors, it aims to reduce motor symptoms such as stiffness, tremors, and bradykinesia, often seen in Parkinson's patients. Clinical studies have explored its efficacy as an adjunct therapy to levodopa, potentially improving symptom management and reducing the "off" periods when medication effects wear off. It is supplied as a high-purity (≥98%) research chemical for laboratory use. Its development highlights its role in addressing unmet needs in neurodegenerative disorders, though clinical advancement was discontinued.